Summary:
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
Qualified Participants Must:
• Be between 18 and 60 years of age
•
Be diagnosed with Schizophrenia
•
Patients currently receiving atypical antipsychotics are eligible provided they are on a stable dose
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.